Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Neurobiol Dis. 2018 Jul 19;119:13–25. doi: 10.1016/j.nbd.2018.07.019

Figure 3. The neuroprotective function of cypin activators is dependent on cypin expression.

Figure 3.

(a,d) Representative traces of mEPSCs recorded from control rat hippocampal neurons or neurons with cypin knockdown treated with vehicle (<0.1% DMSO; control; n=17/23) or 20 μM of the following compounds: H9, (n=6/8), B9 (n=7/8), G5 (n=13/11), or G6 (n=9/8). n=number of neurons/number of cultures. (b,c,e,f) Bar graph analysis of mEPSC frequency and amplitude following 48 hour baseline drug treatment. Pretreatment with H9 increases the frequency of mEPSCs in control neurons with no change to amplitude. (g,j) Representative traces of mEPSCs recorded from rat hippocampal neurons treated with vehicle (<0.1% DMSO; control; n=17/23), or 20μM of the following compounds: NMDA (n=19/16), H9 + NMDA (n=12/12), B9 + NMDA (n=15/11), G5 + NMDA (n=17/12), and G6 + NMDA (n=12/8). n=number of neurons/number of cultures. (h,i,k,l) Bar graph analysis of mEPSC frequency and amplitude following 48 hour drug treatment, 5 minute 20 μM NMDA-induced injury, and two hour recovery period. Treatment with cypin activators prevents the decrease in frequency and amplitude induced by NMDA injury in control neurons, while cypin knockdown causes a loss of function and subsequent decrease of mEPSC frequency and amplitude. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 determined by one-way ANOVA followed by Tukey-Kramer multiple comparisons test. Error bars indicate mean ± SEM.